Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Chandra Mani Adhikari, Dipanker Prajapati, Birat Timalsena, Amrit Bogati, Barkadin Khan, Sajjad Safi, Jagat Adhikari, Vijay Ghimire
BACKGROUND: and objective: Lipid-lowering is an important intervention to reduce cardiovascular morbidity and mortality in the secondary prevention of STEMI. There is no study to analyze the use of statin and LDL-C treatment target attainment among STEMI patients in Nepal. This study aims to assess the use of statin and LDL-C treatment target attainment among STEMI patients. METHODS: It was a prospective observational single-center study conducted at the Shahid Gangalal National Heart Centre, Kathmandu, Nepal outpatient department...
March 31, 2024: Journal of Nepal Health Research Council
#2
RANDOMIZED CONTROLLED TRIAL
Sang-Hyeon Ju, Joung Youl Lim, Minchul Song, Ji Min Kim, Yea Eun Kang, Hyon-Seung Yi, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
OBJECTIVES: Chronic low-grade inflammation is widely recognized as a pathophysiological defect contributing to β-cell failure in type 2 diabetes mellitus (T2DM). Statin therapy is known to ameliorate CD8+ T cell senescence, a mediator of chronic inflammation. However, the additional immunomodulatory roles of ezetimibe are not fully understood. Therefore, we investigated the effect of statin or statin/ezetimibe combination treatment on T cell senescence markers. METHODS: In this two-group parallel and randomized controlled trial, we enrolled 149 patients with T2DM whose low-density lipoprotein cholesterol (LDL-C) was 100 mg/dL or higher...
2024: Frontiers in Endocrinology
#3
JOURNAL ARTICLE
Hacer Kayhan Kaya, Berjan Demirtas, Beran Yokus, Dilek Aygün Kesim, Ezel Tasdemir, Abdurrahman Sermet
Statin treatment may increase the risk of diabetes; there is insufficient data on how statins affect glucose regulation and glycemic control and the effects of statins on liver enzymes related to carbohydrate metabolism have not been fully studied. Therefore, we aimed to compare the effects of the statin derivatives, pravastatin, and rosuvastatin, on carbohydrate metabolism in an experimental diabetic rat model. Female Wistar albino rats were used and diabetes was induced by intraperitoneal injection of streptozotocin...
March 1, 2024: Acta Pharmaceutica
#4
JOURNAL ARTICLE
Yuki Kondo, Masaru Ishida, Takenori Ishisone, Masanobu Niiyama, Takuya Osaki, Yuki Matsumoto, Yuko Maegawa, Kenta Sasaki, Ryo Ninomiya, Yuji Takahashi, Yu Ishikawa, Takumi Kimura, Yudai Shimoda, Munetaka Morikawa, Hidenori Saito, Tomonori Itoh, Yoshihiro Morino
Objective We aimed to reveal detailed on-treatment lipid profiles, lipid-related surrogate markers, and factors predicting failure to achieve the guideline-recommended lipid management goal following guideline-recommended statin treatment in Japanese patients with acute myocardial infarction (AMI). Methods and Results Sixty AMI patients who underwent coronary intervention and had received rosuvastatin 10 mg/day since the start of their hospitalization were assessed for on-treatment lipid-related profiles, including high-sensitivity C-reactive protein, small dense low-density lipoprotein cholesterol (sd LDL-C), and lipoprotein (a), at the 12-week follow-up...
March 18, 2024: Internal Medicine
#5
JOURNAL ARTICLE
Manuel Oliveira-Santos, João Borges-Rosa, Rodolfo Silva, Luís Paixão, Cláudio Espírito Santo, Antero Abrunhosa, Miguel Castelo-Branco, Piotr J Slomka, Lino Gonçalves, Maria João Ferreira
BACKGROUND AND AIMS: Atherosclerotic plaque fluorine-18 sodium fluoride (18 F-NaF) uptake on positron emission tomography with computed tomography (PET-CT) identifies active microcalcification and has been shown to correlate with clinical instability in patients with cardiovascular (CV) disease. Statin therapy promotes coronary macrocalcification over time. Our aim was to investigate rosuvastatin effect on atheroma 18 F-NaF uptake. METHODS: Subjects with high CV risk but without CV events underwent 18 F-NaF-PET-CT in a single-centre...
February 29, 2024: Atherosclerosis
#6
JOURNAL ARTICLE
Carmine Siniscalchi, Behnood Bikdeli, David Jiménez, José María Suriñach, Pablo Demelo-Rodríguez, Farès Moustafa, Aída Gil-Díaz, Alberto García-Ortega, Hanh My Bui, Manuel Monreal
BACKGROUND: The association between statin use and mortality in patients with deep vein thrombosis (DVT) has not been rigorously evaluated. METHODS: We used the data in the RIETE registry to examine the association between statin use and mortality at 3 months. We used mixed effects survival models accounting for clinical covariates and clustering of patients in enrolling centers. RESULTS: From January 2009 through April 2022, there were 46,440 patients with isolated DVT in RIETE (in the lower-limbs 42,291, in the upper limbs 4149)...
April 2024: Thrombosis Research
#7
JOURNAL ARTICLE
Runguo Wu, Claire Williams, Junwen Zhou, Iryna Schlackow, Jonathan Emberson, Christina Reith, Anthony Keech, John Robson, Jane Armitage, Alastair Gray, John Simes, Colin Baigent, Borislava Mihaylova, Jane Armitage, Colin Baigent, Elizabeth Barnes, Lisa Blackwell, Rory Collins, Kelly Davies, Jonathan Emberson, Jordan Fulcher, Heather Halls, William G Herrington, Lisa Holland, Anthony Keech, Adrienne Kirby, Borislava Mihaylova, Rachel O'Connell, David Preiss, Christina Reith, John Simes, Kate Wilson, Michael Blazing, Eugene Braunwald, James de Lemos, Sabina Murphy, Terje R Pedersen, Marc Pfeffer, Harvey White, Stephen Wiviott, Michael Clearfield, John R Downs, Antonio Gotto, Stephen Weis, Bengt Fellström, Hallvard Holdaas, Alan Jardine, Terje R Pedersen, David Gordon, Barry Davis, Curt Furberg, Richard Grimm, Sara Pressel, Jeffrey L Probstfield, Mahboob Rahman, Lara Simpson, Michael Koren, Björn Dahlöf, Ajay Gupta, Neil Poulter, Peter Sever, Hans Wedel, Robert H Knopp, Stuart Cobbe, Bengt Fellström, Hallvard Holdaas, Alan Jardine, Roland Schmieder, Faiez Zannad, D John Betteridge, Helen M Colhoun, Paul N Durrington, John Fuller, Graham A Hitman, Andrew Neil, Eugene Braunwald, Barry Davis, C Morton Hawkins, Lemuel Moyé, Marc Pfeffer, Frank Sacks, John Kjekshus, Hans Wedel, John Wikstrand, Christoph Wanner, Vera Krane, Maria Grazia Franzosi, Roberto Latini, Donata Lucci, Aldo Maggioni, Roberto Marchioli, Enrico B Nicolis, Luigi Tavazzi, Gianni Tognoni, Jackie Bosch, Eva Lonn, Salim Yusuf, Jane Armitage, Louise Bowman, Rory Collins, Anthony Keech, Martin Landray, Sarah Parish, Richard Peto, Peter Sleight, John Jp Kastelein, Terje R Pedersen, Robert Glynn, Antonio Gotto, John Jp Kastelein, Wolfgang Koenig, Jean MacFadyen, Paul M Ridker, Anthony Keech, Stephen MacMahon, Ian Marschner, Andrew Tonkin, John Shaw, John Simes, Harvey White, Patrick W Serruys, Genell Knatterud, Gerard J Blauw, Stuart Cobbe, Ian Ford, Peter Macfarlane, Chris Packard, Naveed Sattar, James Shepherd, Stella Trompet, Eugene Braunwald, Christopher P Cannon, Sabina Murphy, Rory Collins, Jane Armitage, Louise Bowman, Richard Bulbulia, Richard Haynes, Sarah Parish, Richard Peto, Peter Sleight, Pierre Amarenco, K Michael Welch, John Kjekshus, Terje R Pedersen, Lars Wilhelmsen, Philip Barter, Antonio Gotto, John LaRosa, John Jp Kastelein, James Shepherd, Stuart Cobbe, Ian Ford, Sharon Kean, Peter Macfarlane, Chris Packard, Michele Roberston, Naveed Sattar, James Shepherd, Robin Young, Hiroyuki Arashi, Robert Clarke, Marcus Flather, Shinya Goto, Uri Goldbourt, Jemma Hopewell, G Kees Hovingh, George Kitas, Connie Newman, Marc S Sabatine, Gregory G Schwartz, Liam Smeeth, Jonathan Tobert, John Varigos, Junichi Yamamguchi
BACKGROUND: UK cardiovascular disease (CVD) incidence and mortality have declined in recent decades but socioeconomic inequalities persist. AIM: To present a new CVD model, and project health outcomes and the impact of guideline-recommended statin treatment across quintiles of socioeconomic deprivation in the UK. DESIGN AND SETTING: A lifetime microsimulation model was developed using 117 896 participants in 16 statin trials, 501 854 UK Biobank (UKB) participants, and quality-of-life data from national health surveys...
February 19, 2024: British Journal of General Practice
#8
JOURNAL ARTICLE
Rosangela A Hoshi, Branimir Plavša, Yanyan Liu, Irena Trbojević-Akmačić, Robert J Glynn, Paul M Ridker, Richard D Cummings, Ivan Gudelj, Gordan Lauc, Olga V Demler, Samia Mora
BACKGROUND: Posttranslational glycosylation of IgG can modulate its inflammatory capacity through structural variations. We examined the association of baseline IgG N-glycans and an IgG glycan score with incident cardiovascular disease (CVD). METHODS: IgG N-glycans were measured in 2 nested CVD case-control studies: JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; NCT00239681, primary prevention; discovery; Npairs=162); and TNT trial (Treating to New Targets; NCT00327691, secondary prevention; validation; Npairs=397)...
February 13, 2024: Circulation Research
#9
EDITORIAL
Eun Roh
No abstract text is available yet for this article.
January 2024: Diabetes & Metabolism Journal
#10
RANDOMIZED CONTROLLED TRIAL
Mohammad Taghi Gorji, Fariba Alaei-Shahmiri, Gisoo Darban Hosseini Amirkhiz, Seyed Hashem Sezavar, Mojtaba Malek, Mohammad E Khamseh
BACKGROUND: The aim of this study was to compare moderate- versus high-intensity statin therapy in patients with type 2 diabetes and low-density lipoprotein (LDL) cholesterol less than 130 mg/dL. METHODS: This was a randomized, open-label, parallel design trial comprised of 79 patients randomly allocated into two groups receiving high-intensity [atorvastatin 40 mg (A40) or rosuvastatin 20 mg (R20) daily] or moderate-intensity [atorvastatin 20 mg (A20) or rosuvastatin 10 (R10) mg daily] statins for eight weeks...
June 1, 2023: Archives of Iranian Medicine
#11
Avish K Jain, Aditi Shah, Geetha Bhat
BACKGROUND/OBJECTIVE: Olanzapine is a second-generation antipsychotic medication with increased side effects of weight gain, hyperglycemia, and insulin resistance. Here we describe a case of diabetic ketoacidosis in a patient who started taking olanzapine 12 weeks before she presented. CASE REPORT: A 73-year-old African-American female presented with a 1-week history of confusion, polyuria, and polydipsia. Her past medical history included type 2 diabetes mellitus, hyperlipidemia, and severe depression with psychotic features...
2024: AACE Clinical Case Reports
#12
RANDOMIZED CONTROLLED TRIAL
Ji Hye Han, Kyong Hye Joung, Jun Choul Lee, Ok Soon Kim, Sorim Choung, Ji Min Kim, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Bon Jeong Ku, Hyun Jin Kim
BACKGRUOUND: Type 2 diabetes mellitus (T2DM) induces endothelial dysfunction and inflammation, which are the main factors for atherosclerosis and cardiovascular disease. The present study aimed to compare the effects of rosuvastatin monotherapy and rosuvastatin/ezetimibe combination therapy on lipid profile, insulin sensitivity, and vascular inflammatory response in patients with T2DM. METHODS: A total of 101 patients with T2DM and dyslipidemia were randomized to either rosuvastatin monotherapy (5 mg/day, n=47) or rosuvastatin/ezetimibe combination therapy (5 mg/10 mg/day, n=45) and treated for 12 weeks...
January 2024: Diabetes & Metabolism Journal
#13
EDITORIAL
Ichiro Sakuma
No abstract text is available yet for this article.
December 28, 2023: Arteriosclerosis, Thrombosis, and Vascular Biology
#14
RANDOMIZED CONTROLLED TRIAL
Jun Sung Moon, Il Rae Park, Sang Soo Kim, Hye Soon Kim, Nam Hoon Kim, Sin Gon Kim, Seung Hyun Ko, Ji Hyun Lee, Inkyu Lee, Bo Kyeong Lee, Kyu Chang Won
BACKGRUOUND: To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high atherosclerotic cardiovascular disease (ASCVD) risk patients with type 2 diabetes mellitus (T2DM). METHODS: This study was a randomized, multicenter, open, parallel phase 4 study, and enrolled T2DM subjects with an estimated 10-year ASCVD risk ≥7.5%. The primary endpoint was the low-density lipoprotein cholesterol (LDL-C) change rate after 24-week rosuvastatin 10 mg/ezetimibe 10 mg treatment was non-inferior to that of rosuvastatin 20 mg...
November 2023: Diabetes & Metabolism Journal
#15
JOURNAL ARTICLE
Seung-Jun Lee, Jae Hong Joo, Sohee Park, Choongki Kim, Dong-Woo Choi, Yong-Joon Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Chung-Mo Nam, Myeong-Ki Hong
AIMS: Using rosuvastatin, the RACING (randomized comparison of efficacy and safety of lipid-lowering with statin monotherapy versus statin/ezetimibe combination for high-risk cardiovascular diseases) trial showed the beneficial effects of combining moderate-intensity statin with ezetimibe compared with high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease. This study investigated whether the beneficial effects of combination lipid-lowering therapy extend to patients treated with atorvastatin, not rosuvastatin, in daily clinical practice...
November 10, 2023: European Heart Journal. Cardiovascular Pharmacotherapy
#16
JOURNAL ARTICLE
Jung-Min Yu, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu
PURPOSE: To investigate the impact of statin use on primary prevention of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) in a dose-, class-, and use intensity-dependent manner. METHODS: We used an inverse probability treatment-weighted Cox hazards model, with statin use status as a time-dependent variable. RESULTS: Our results showed that statin use was associated with a significant reduction in CVD risk with an adjusted hazard ratio of 0...
2023: Diabetes & Vascular Disease Research
#17
JOURNAL ARTICLE
Maki Komamine, Yoshiaki Fujimura, Masatomo Omiya, Tosiya Sato
BACKGROUND: To evaluate missing data methods applied to laboratory test results used for confounding adjustment, utilizing data from 10 MID-NET® -collaborative hospitals. METHODS: Using two scenarios, five methods dealing with missing laboratory test results were applied, including three missing data methods (single regression imputation (SRI), multiple imputation (MI), and inverse probability weighted (IPW) method). We compared the point estimates of adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) between the five methods...
October 30, 2023: BMC Medical Informatics and Decision Making
#18
JOURNAL ARTICLE
Zhao Zhao, Xinpeng Wang, Meili Lu, Yuxia Gao
BACKGROUND: Rosuvastatin contributes to the improvement of vascular complications in diabetes, but the protective mechanisms remain unclear. The aim of the present study was to investigate the effect and mechanism of rosuvastatin on endothelial dysfunction induced by diabetes. METHODS: Calpain-1 knockout (Capn1 EK684-/-) and C57BL/6 mice were intraperitoneally injected with STZ to induce type 1 diabetes. Human umbilical vein endothelial cells (HUVECs) were incubated with high glucose in this study...
October 20, 2023: Current Pharmaceutical Design
#19
RANDOMIZED CONTROLLED TRIAL
Yong-Joon Lee, Sung-Jin Hong, Woong Chol Kang, Bum-Kee Hong, Jong-Young Lee, Jin-Bae Lee, Hyung-Jin Cho, Junghan Yoon, Seung-Jun Lee, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong
OBJECTIVE: To compare the long term efficacy and safety of rosuvastatin with atorvastatin treatment in adults with coronary artery disease. DESIGN: Randomised, open label, multicentre trial. SETTING: 12 hospitals in South Korea, September 2016 to November 2019. PARTICIPANTS: 4400 adults (age ≥19 years) with coronary artery disease. INTERVENTIONS: Participants were assigned to receive either rosuvastatin (n=2204) or atorvastatin (n=2196) using 2×2 factorial randomisation...
October 18, 2023: BMJ: British Medical Journal
#20
JOURNAL ARTICLE
Jihoon Kwon, Michelle S Kim, Christina Blagojevic, Jaymie Mailloux, Samantha Medwid, Rommel G Tirona, Rennian Wang, Ute I Schwarz
An increased risk of new-onset diabetes mellitus has been recently reported for statin therapy, and experimental studies have shown reduced glucose-stimulated insulin secretion (GSIS) and mitochondrial dysfunction in beta cells with effects differing among agents. Organic anion transporting polypeptide (OATP) 2B1 contributes to hepatic uptake of rosuvastatin, atorvastatin and pravastatin, three known substrates. Since OATP2B1 is present in beta cells of the human pancreas, we investigated if OATP2B1 facilitates the local accumulation of statins in a rat beta cell model INS-1 832/13 (INS-1) thereby amplifying statin-induced toxicity...
September 28, 2023: Toxicology Mechanisms and Methods
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
